Barale et al. in their study claimed that in patients with hypercholesterolemia the inhibition of PCSK9 with alirocumab or evolocumab results in increased platelet responsiveness to acetylsalicylic acid [58]. Here, PCSK9 is linked to familial hypercholesterolemia.